title: How might treatment of ALK-positive non-small cell lung cancer change in the near future?
authors.affiliation: a Medical Oncology , Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia , Perugia , Italy.
authors.forename: Giulio
authors.initials: G
authors.lastname: Metro
authors.affiliation: b Department of Experimental Medicine, Division of Pathology and Histology , University of Perugia Medical School , Perugia , Italy.
authors.forename: Guido
authors.initials: G
authors.lastname: Bellezza
authors.affiliation: c Department of Thoracic Surgery , Santa Maria della Misericordia Hospital, University of Perugia Medical School , Perugia , Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Puma
authors.affiliation: a Medical Oncology , Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia , Perugia , Italy.
authors.forename: Rita
authors.initials: R
authors.lastname: Chiari
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D015195:Drug Design; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases
keywords: ALK; ALK-TKI; Alectinib; central nervous system metastases; ceritinib; crizotinib; lorlatinib; non-small cell lung cancer